SCHEMBL1765944

SCHEMBL1765944

Cc1cc([C@H](O)CCc2sc(-c3ccc(C(F)(F)F)cc3)nc2C(C)C)ccc1OCC(=O)O

nearest known ligand 0.62

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 20/20 0.62
PPARA Q07869 9/20 0.62
PPARG P37231 5/20 0.62
FFAR1 O14842 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12732524 1.00 PPARD (0.62) PPARDPPARAPPARGFFAR1
SCHEMBL4751894 1.00 PPARD (0.62) PPARDPPARAPPARGFFAR1
SCHEMBL4787001 1.00 PPARD (0.62) PPARDPPARAPPARGFFAR1
SCHEMBL12732463 0.93 PPARD (0.53) PPARDPPARAPPARGFFAR1
SCHEMBL12648505 0.92 PPARD (0.52) PPARDPPARAPPARGFFAR1
SCHEMBL12732536 0.92 PPARD (0.52) PPARDPPARAPPARGFFAR1
SCHEMBL5656813 0.91 PPARD (0.76) PPARDPPARAPPARGFFAR1
SCHEMBL23870961 0.89 PPARD (0.49) PPARDPPARAPPARG
SCHEMBL23870963 0.89 PPARD (0.49) PPARDPPARAPPARG
SCHEMBL23870983 0.89 PPARD (0.49) PPARDPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2464349-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES Cerenis Therapeutics S.A. (FR) 2012-06-20 EP disclosed
WO-2011020001-A9 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-05-26 WO disclosed
WO-2011020001-A9 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-05-26 WO disclosed
US-20110092517-A1 Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases Cerenis Therapeutics S.A. & Nippon Chemiphar Co., Ltd. 2011-04-21 US disclosed
US-20110092517-A1 Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases Cerenis Therapeutics S.A. & Nippon Chemiphar Co., Ltd. 2011-04-21 US disclosed
WO-2011020001-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-02-17 WO disclosed
WO-2011020001-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-02-17 WO disclosed
WO-2008154023-A1 NOVEL USES OF PPAR DELTA AGONISTS CERENIS THERAPEUTICS S.A. (FR) 2008-12-18 WO disclosed
WO-2008154023-A1 NOVEL USES OF PPAR DELTA AGONISTS CERENIS THERAPEUTICS S.A. (FR) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092517-A1 Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases PPARD, PPARG, PPARA PPARD 1/4885PPARA 3/4885PPARG 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.